New imaging agent could sharpen prostate cancer detection
NCT ID NCT06101927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested a new radioactive tracer called [99mTc]Tc-BQ0413 in 10 men with prostate cancer. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it goes in the body and how safe it is. The goal is to develop a better imaging tool for prostate cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m BQ0413 ([99mTc]Tc-BQ0413) - a radioactive tracer for imaging
What this could lead to
If successful, this could lead to a new imaging method to better detect and monitor prostate cancer using SPECT scans.
What could go wrong
This is a very early Phase 1 study with only 10 participants, so results may not apply broadly. The tracer's imaging accuracy compared to standard methods is still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia